Cal Strode
Cal Strode is a communications consultant specializing in health, science, and innovation, with experience in these sectors across the UK, Canada, and U.S. Previously, he was the Manager, Communications at CCRM. Before that, he worked with the UK’s National Institute for Health Research (NIHR) Applied Research Collaboration North West Coast (ARC NWC) and UK Research & Innovation’s (UKRI) 3DBioNet network. He also has five years of public health communications experience, delivering national campaigns with measurable impact in the fields of mental and sexual health. With an interest in how effective communications can catalyze change, his undergraduate thesis on the topic won the European Public Relations Education and Research Association (EUPRERA) award, which led to him presenting his findings at EUPRERA’s congress in Brussels. Outside of work, he enjoys surfing and open-water swimming. Follow him on X @CalStrode.
Posts by: Cal
From innovation to international impact: ARM’s 2025 “State of the Industry Briefing” showcases maturing CGT industry
2025 marks the third time I’ve covered the Alliance for Regenerative Medicine (ARM) State of the Industry Briefing for Signals. In 2024’s installation, I noted the strong emphasis on the cell and gene therapy (CGT) industry’s acceleration, driven by scientific advances bringing meaningful developments for patients. This year, I noticed a remarkable paradigm shift as […]
What’s in store for 2024: ARM’s “State of the Industry Briefing” for cell and gene therapy
About a year ago today, I covered the 2023 Alliance for Regenerative Medicine (ARM) State of the Industry Briefing for Signals. The briefing placed strong emphasis on the industry’s acceleration, driven by scientific advances that are bringing meaningful developments for patients. That acceleration has since accelerated. Tim Hunt, CEO, ARM, delivered a dose of optimism […]
What’s in the mix for 2026: ARM’s State of the Industry briefing
This year marks the fourth consecutive time I’ve covered the Alliance for Regenerative Medicine’s (ARM) State of the Industry briefing for Signals, and I’ve enjoyed tracking how the cell and gene therapy sector has evolved in real time. In 2023 and 2024, the briefings were defined by acceleration, scientific momentum, and the promise of breakthrough […]